Inpatient Outpatient Other Facility Unable to obtain follow up information
|
|
- Alannah Farmer
- 5 years ago
- Views:
Transcription
1 version date: 12/10/ Month Followup Followup Status (1 Month Followup (+/ 7 days)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain follow up information Follow up date Facility Type Nursing Home/Assisted Care Hospice Another hospital Rehabilitation Facility State reason why you are unable to obtain follow up information Patient didn't come to clinic t able to contact patient t addressed by site Was patient intubated? Was patient on dialysis? Pump Change Pump Exchange If yes, please select one of the following: Please select appropriate reason: Intracorporeal device Para or Extra corporeal device Upsizing device because of patient growth status All other reasons would categorize the pump change as a Device Malfunction Thrombus NOT associated with hemolysis Change in hemodynamics Clinical status Device parameters Was there a Console Change? 1 of 14
2 1 Month Followup - Status version date: 12/10/2015 Date of console change ST= Original Console Name New Console Name Medical Condition NYHA Class Class I: limitation of physical activity; physical activity does not cause fatigue, palpitation or shortness of breath. Class II: Slight limitation of physical activity; comfortable at rest, but ordinary physical activity results in fatigue, palpitations or shortness of breath. Class III: Marked limitation of physical activity; comfortable at rest, but less than ordinary activity causes fatigue, palpitation or shortness of breath. Class IV: Unable to carry on minimal physical activity without discomfort; symptoms may be present at rest. Ross Classification of Congestive Heart Failure Ross Class I: limitations or symptoms. Ross Class II: growth failure. Ross Class III: Growth failure. Ross Class IV: Symptomatic at rest. t applicable: >= 2 years of age Choose all indicated symptoms that apply. Choose all indicated symptoms that apply. Choose all indicated symptoms that apply. Mild tachypnea with feeds in infant Mild diaphoresis with feeds in infant Dyspnea on exercise in older children Marked tachypnea with exertion or with feeding Marked diaphoresis with exertion or with feeding Tachypnea Retractions Grunting Diaphoresis Functional Capacity Sedated Paralyzed Intubated 2 of 14
3 1 Month Followup - Status version date: 12/10/2015 Ambulating Primary Nutrition Orally Per feeding tube TPN t Applicable Excursions Has the patient had any nonmedically required excursions off the unit? If yes, where (please select all that apply) t Applicable Playroom Cafeteria Walk outside Sitting room General rehab ne ZONES Hemolysis Zone Please enter the peak Plasma free hemoglobin (PFH) since the last visit: ST= t Done What is your hospital s upper limit of the normal range of peak PFH? ST= t Done Please enter the peak serum lactate dehydrogenase (LDH) since the last visit: ST= t Done What is your hospital s upper limit of the normal range of LDH? ST= t Done Enter the Maximum and Minimum HCT or HGB since the last visit. Min. HCT: ST= t Done Max. HCT: 3 of 14
4 1 Month Followup - Status version date: 12/10/2015 ST= t Done Min. HGB: ST= t Done Max. HGB: ST= t Done Highest Total Bilirubin since the last visit: ST= t Done Has the following been present at any time since the last visit? Physical Findings (select all that apply): Hemoglobinuria (Tea Colored Urine)? Pump malfunction and/or abnormal pump parameters? Right Heart Failure Zone Clinical Findings Since the last visit. CVP or RAP > 16 mmhg? Dilated Vena Cava with absence of Inspiratory Variation by Echo? Clinical findings of elevated jugular venous distension at least half way up the neck in an upright patient? Peripheral Edema? Ascites? 4 of 14
5 1 Month Followup - Status version date: 12/10/2015 Has the patient been on Inotropes since the last visit? If yes, select all that apply: Dopamine Dobutamine Milrinone Isoproterenol Epinephrine repinephrine Levosimendan Vasopressin Nitroprusside Fenoldopam Prostacyclin Nesiritide? Has the patient had a RVAD implant since the last visit? Has the patient experienced a Neurological Event since time of implant? If yes, provide Modified Rankin Scale: 0 symptoms at all 1 Significant disability: despite symptoms: able to carry out all usual duties and activities 2 Slight disability: unable to carry out all previous activities but able to look after own affairs without assistance 3 Moderate disability: requiring some help, but able to walk without assistance. 4 Moderately severe disability: unable to walk without assistance, and unable to attend to own bodily needs without assistance. 5 Severe disability: bedridden, incontinent and requiring constant nursing care and attention. 6 Dead ST= t Documented t Done 5 of 14
6 version date: 12/10/ Month Followup Hemodynamics General Hemodynamics Systolic blood pressure ST= t done mmhg Diastolic blood pressure ST= t done mmhg Mean Arterial Blood Pressure (MAP) mmhg ST= t done ECG rhythm Sinus Atrial fibrillation Atrial Flutter Paced: Atrial pacing Paced: Ventricular pacing Paced: Atrial and ventricular pacing t done Other, specify Height ST= t done in cm Weight ST= t done lbs kg Invasive Hemodynamics Date of Measurement ST= t Done Pulmonary artery systolic pressure ST= t Done mmhg 6 of 14
7 1 Month Followup - Hemodynamics version date: 12/10/2015 Pulmonary artery diastolic pressure ST= t Done mmhg Mean RA Pressure ST= t Done mmhg PVR wood units ST= t Done Mean Pulmonary artery wedge pressure ST= t Done mmhg Central venous pressure (CVP) mmhg ST= t Done Cardiac Index ST= t Done L/min/M 2 (by Swan) Fick ST= t Done L/min/M 2 Thermodilution ST= t Done L/min/M 2 7 of 14
8 version date: 12/10/ Month Followup Medications Was the patient sent home with an IV? ACE inhibitors Aldosterone antagonist Amiodarone Angiotensin receptor blocker drug Antiplatelet therapy drug Select drug(s) Aspirin Dextran Dipyridamole Clopidogrel Ticlopidine Other, specify Thrombolytic Beta blockers Calcium channel blockers Digoxin 8 of 14
9 1 Month Followup - Medications version date: 12/10/2015 Hydralazine Loop diuretics If yes, enter dosage: mg/day ST= Type of Loop Diuretic: Furosemide Torsemide Bumetanide Other Low molecular weight heparin (Lovenox, Fragmin, Innohep) Unfractionated heparin Nitric oxide Sildenafil/ Bosentan UFH: Unfractionated Heparin Warfarin (coumadin) Arixtra (fondaparinux) Did patient receive new IV or oral medication to treat hypertension? Transfusion Was there a Tranfusion? 9 of 14
10 1 Month Followup - Medications version date: 12/10/2015 If yes, enter number of PRBC (Total number of cc's received) ST= 10 of 14
11 version date: 12/10/ Month Followup Laboratory Sodium meq/l ST= t done mmol/l Potassium meq/l ST= t done mmol/l Blood urea nitrogen mg/dl ST= t done mmol/l Creatinine mg/dl ST= t done umol/l SGPT/ALT (alanine aminotransferase/alt) ST= t done u/l SGOT/AST (aspartate aminotransferase/ast) ST= t done u/l LDH units/l, U/L, ukat/l ST= t done Total bilirubin mg/dl ST= t done umol/l Bilirubin direct mg/dl ST= t Done umol/l 11 of 14
12 1 Month Followup - Laboratory version date: 12/10/2015 Bilirubin indirect mg/dl ST= t Done umol/l Albumin g/dl ST= t done g/l Pre albumin mg/dl ST= t done mg/l Total Cholesterol ST= < 50 mg/dl t done mg/dl mmol/l Brain natriuretic peptide BNP ST= > 7500 pg/ml t done pg/ml ng/l NT pro brain natriuretic peptide Pro BNP ST= t done pg/ml ng/l White blood cell count ST= t done x10 3 /ul x10 9 /ul Reticulocyte count % ST= t Done Hemoglobin g/dl ST= t done g/l mmol/l 12 of 14
13 1 Month Followup - Laboratory version date: 12/10/2015 Platelets x10 3 /ul ST= t done x10 9 /ul INR international units ST= t done Plasma free hemoglobin mg/dl ST= t Done g/l Positive antiheparin/platelet antibody (HIT) If, are they on direct thrombin inhibitors If, Enter Drugs: Aspirin Dipyridamole Plavix Heparin Coumadin Direct thrombin inhibitors (ex: arg, lip, val ) Was a TEG done? ThrombElastoGraph Hemostasis System (TEG) profile, MA k ThrombElastoGraph Hemostasis System (TEG) profile, R k ThrombElastoGraph HemostasisSystem (TEG) profile, R h ST= t Done ST= t Done ST= t Done max amplitude in kaolin reaction time in kaolin reaction time w/heparinase CRP or hs CRP ST= t done mg/dl Lupus Anticoagulant Positive Negative 13 of 14
14 1 Month Followup - Laboratory version date: 12/10/ of 14
1 Month Followup - Pedimacs
version date: 03/27/2018 1 Month Followup - Pedimacs Followup Status (1 Month Followup (+/- 7 days)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain follow-up information
More information1 Week Followup - Intermacs
version date: 9/27/2017 1 Week Followup - Intermacs Followup Status (1 Week Followup (+/- 3 days)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain follow-up information
More information1 Week Followup 5/27/2014. Nursing Home/Assisted Care Hospice Another hospital Rehabilitation Facility Unknown
1 Week Followup t Started Please answer all questions considering all time since the previous visit and current follow-up date. Print this Form Followup Status t Started Select one of the following Inpatient
More informationFollowup Status (1 Week Followup (+/- 3 days))
1 Week Followup - Status version date: 09/27/2018 Intermacs 1 Week Followup Followup Status (1 Week Followup (+/- 3 days)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain
More informationFollowup 5/27/2014. Nursing Home/Assisted Care Hospice Another hospital Rehabilitation Facility Unknown
3 Month Followup t Started Please answer all questions considering all time since the previous visit and current follow-up date. Print this Form Followup Status t Started Select one of the following Inpatient
More information3 Month / 6 Month Follow-Up
3 Month / 6 Month Follow-Up Select one of the following:* Follow-up date:* Facility Type:* State reason why you are unable to obtain follow-up information:* General Hemodynamics - during report interval
More information: 2014 INTERMACS 4.0 Launches June 2, 2014
: 2014 INTERMACS 4.0 Launches June 2, 2014 David C. Naftel, PhD 1 June 2006 March 2014 UAB: DCC UNOS: WBDE 2 : 2006 What patients are receiving MCSDs? Do DT patients ever receive a transplant? What are
More informationAdverse Event Not Started
Adverse Event t Started Adverse Event Status Print this Form t Started Please enter the date of the event you are reporting: Please enter a label describing this event: 2014 InterMACS [InterMACS_New] 1
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More information3 Month Followup - Intermacs
3 Month Followup - Intermacs Followup Status (3 Month Followup (+/- 1 month)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain follow-up information Follow-up date Facility
More information3 Month Followup - Intermacs
3 Month Followup - Status version date: 06/28/2018 3 Month Followup - Intermacs Followup Status (3 Month Followup (+/- 1 month)) Select one of the following Inpatient Outpatient Other Facility Unable to
More information3 Month Followup - Intermacs
version date: 12/19/2017 3 Month Followup - Intermacs Followup Status (3 Month Followup (+/- 1 month)) Select one of the following Inpatient Outpatient Other Facility Unable to obtain follow-up information
More informationPre-Implant. Demographics Height:* in cm ST = Weight:* lbs kgs ST = Blood type:*
Pre-Implant Demographics Height:* in cm ST = Weight:* lbs kgs ST = Blood type:* Medical Support Status Current Device Strategy at time of implant:* Enter List Date:* mm/dd/yyyy ST= Concerns / Contraindications
More informationFollowup Status (3 Month Followup (+/- 1 month))
3 Month Followup - Status version date: 09/27/2018 Intermacs 3 Month Followup Followup Status (3 Month Followup (+/- 1 month)) Select one of the following Inpatient Outpatient Other Facility Unable to
More informationGWTG Post-Discharge Follow-up Form
Bold font = Required field Patient ID: Date of Hospital Admission: / / mm / dd / yyyy Date Follow-up Completed: / / mm / dd / yyyy PATIENT LOGISTICS Method used for Patient follow-up: Chart Review Health
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationAdverse Event - Intermacs
version date: 6/28/2017 Adverse Event - Intermacs Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 24 version date: 6/28/2017
More informationARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM. General Instructions: ID NUMBER: FORM NAME: H F A DATE: 10/13/2017 VERSION: CONTACT YEAR NUMBER:
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM General Instructions: The Heart Failure Hospital Record Abstraction Form is completed for all heart failure-eligible cohort hospitalizations. Refer to
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationForm 8: Post Transplant Annual Followup
Page 1 of 8 Patient Details Hidden Show Show/Hide Annotations Stickies: Toggle All Toggle Open Toggle Resolved Form 8: Post Transplant Annual Followup Toggle Question Year/Info Print this Form t Started
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationTips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance
Tips & tricks on how to treat an acute heart failure patient with low cardiac output and diuretic resistance J. Parissis Attikon University Hospital, Athens, Greece Disclosures ALARM investigator received
More informationMedical Treatment for acute Decompensated Heart Failure. Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011
Medical Treatment for acute Decompensated Heart Failure Vlasis Ninios Cardiologist St. Luke s s Hospital Thessaloniki 2011 2010 HFSA guidelines for ADHF 2009 focused update of the 2005 American College
More informationEvaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF<40%
Evaluation and Management of Acute Decompensated Heart Failure (HF) with Reduced Ejection Fraction Systolic Heart Failure (HFrEF)(EF
More informationDisclosure Information : No conflict of interest
Intravenous nicorandil improves symptoms and left ventricular diastolic function immediately in patients with acute heart failure : a randomized, controlled trial M. Shigekiyo, K. Harada, A. Okada, N.
More informationARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM
ARIC HEART FAILURE HOSPITAL RECORD ABSTRACTION FORM ID NUMBER: FORM NAME: H F A DATE: 10/01/2015 VERSION: D CONTACT YEAR NUMBER: FORM SEQUENCE NUMBER: General Instructions: The Heart Failure Hospital Record
More informationAdverse Event. Adverse Event Status. version date: 12/10/ of 21. Please enter the date of the event you are reporting:
version date: 12/10/2015 Adverse Event Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 21 version date: 12/10/2015 Adverse Event
More informationForm 8: Post Transplant Annual Followup
Page 1 of 7 Show trials/registries Patient Details Hidden Show Show/Hide Annotations Stickies: Toggle All Toggle Open Toggle Resolved Form 8: Post Transplant Annual Followup Print this Form t Started 1
More informationIN-HF on line: patient settings (Enrollement period= )
IN-HF on line: atient settings (Enrollement eriod= 1995-2018) N of centers (total) 187 N of centers (ts. AHF only) 13 N of centers (ts. CHF only) 71 N of centers (both ts. AHF and CHF) 103 N of atients
More informationPre-discussion questions
Amanda Bartlett, PA-C Dustin Bartlett, PA-C Andrea Applegate, PA-C Leslie Yearta Brown, NP CHF Round Table Discussion Objectives ANDREA- Discuss the definition and different categories of CHF DUSTIN- Define
More informationVentricular Assist Devices
Page 1 By Tonya Elliott, RN, MSN Background, Indications for VADs Mechanical circulatory support has become an acceptable therapy for end stage heart failure (HF) in maximally medically treated patients
More informationAdverse Event. Adverse Event Status. Please enter the date of the event you are reporting: Please enter a label describing this event:
Adverse Event Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 17 Adverse Event Infection Was there a major infection? Date of
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationAdverse Event - Pedimacs
version date: 12/19/2017 Adverse Event - Pedimacs Adverse Event Status Please enter the date of the event you are reporting: Please enter a label describing this event: 1 of 22 version date: 12/19/2017
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationRevision of 10/27/2017 Form #280 Page 1 of 12 PVDOMICS STUDY Clinical Center Right Heart Catheterization (RHC) Results Form #280
Revision of 10/27/2017 Form #280 Page 1 of 12 PVDOMICS STUDY Clinical Center Right Heart Catheterization (RHC) Results Form #280 Instructions: Review PVDOMICS MOP Chapter 100 prior to completing right
More information4 Has this patient been transplanted No
Form 1RL: Relisting Print this Form t Started 1 Date of Relisting Height and Weight 2 Height Centimeters Inches Calculated BSA: n/a BMI: n/a 3 Weight Kilograms Pounds 4 Has this patient been transplanted
More informationVolume 3 (2017) Issue 23 ISSN Abstract. Keywords. Learning Objective. Introduction. Open Journal of Clinical & Medical Case Reports
Open Journal of Clinical & Medical Case Reports Volume 3 (2017) Issue 23 ISSN 2379-1039 Severe pulmonary hypertension secondary to anagrelide treatment? George Calcaianu*; Mihaela Calcaianu; Guillaume
More information5/30/2014. Pulmonary Hypertension PULMONARY HYPERTENSION. mean PAP > 25 mmhg at rest. Disclosure: none
Disclosure: Pulmonary Hypertension none James Ramsay MD Medical Director, CV ICU, Moffitt Hospital, UCSF PULMONARY HYPERTENSION mean PAP > 25 mmhg at rest Pulmonary Hypertension and Right Ventricular Dysfunction:
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationCardiorenal and Renocardiac Syndrome
And Renocardiac Syndrome A Vicious Cycle Cardiorenal and Renocardiac Syndrome Type 1 (acute) Acute HF results in acute kidney injury Type 2 Chronic cardiac dysfunction (eg, chronic HF) causes progressive
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationDEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University
DEMYSTIFYING VADs Nicolle Choquette RN MN Athabasca University Objectives odefine o Heart Failure o VAD o o o o Post Operative Complications Acute Long Term Nursing Interventions What is Heart Failure?
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationImages have been removed from the PowerPoint slides in this handout due to copyright restrictions.
Heart Failure Heart Failure Introduction and History AHA 2015 Statistics About 6 million Americans 870,000 new cases each year 1 in 9 deaths related to HF Almost 1 million hospitalizations each year (cost
More informationCardiac Drugs: Chapter 9 Worksheet Cardiac Agents. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate.
Complete the following. 1. drugs affect the rate of the heart and can either increase its rate or decrease its rate. 2. drugs affect the force of contraction and can be either positive or negative. 3.
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationAcute heart failure, beyond conventional treatment: persisting low output
Acute heart failure, beyond conventional treatment: persisting low output Alexandre Mebazaa, FESC Hôpital Lariboisière, Université Paris 7 U942 Inserm Conflict of Interest Lecture fee: Orion No other conflicts
More informationTables of Normal Values (As of February 2005)
Tables of Normal Values (As of February 2005) Note: Values and units of measurement listed in these Tables are derived from several resources. Substantial variation exists in the ranges quoted as normal
More informationTopic Page: congestive heart failure
Topic Page: congestive heart failure Definition: congestive heart f ailure from Merriam-Webster's Collegiate(R) Dictionary (1930) : heart failure in which the heart is unable to maintain an adequate circulation
More informationAtrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.
Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:
More informationMedical Management of Acutely Decompensated Heart Failure. William T. Abraham, MD Director, Division of Cardiovascular Medicine
Medical Management of Acutely Decompensated Heart Failure William T. Abraham, MD Director, Division of Cardiovascular Medicine Orlando, Florida October 7-9, 2011 Goals of Acute Heart Failure Therapy Alleviate
More informationPatient Encounters in the Primary Care Setting
Patient Encounters in the Primary Care Setting Carmine D Amico, D.O. Clinical Cases Overview Learning objectives Clinical case presentations Questions for audience participation 1 Clinical Cases Learning
More informationHeart Failure. Dr. Alia Shatanawi
Heart Failure Dr. Alia Shatanawi Left systolic dysfunction secondary to coronary artery disease is the most common cause, account to 70% of all cases. Heart Failure Heart is unable to pump sufficient blood
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationSA XXXX Special Authority for Subsidy
SA XXXX Special Authority for Subsidy Special authority approved by the Pulmonary Arterial Hypertension (PAH) Panel. Application forms can be obtained from PHARMAC s website: www.pharmac.govt.nz or: PAH
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationExercise Prescription for Patients with CHF
Exercise Prescription for Patients with CHF LESLIE AYRES, PT, DPT Goals After viewing this presentation the physical therapist will be able to: Discuss and understand the diagnosis of CHF including: Clinical
More information3.1 Name of the Source of Registration (OPD/ICU/Ward Name) Hospital Registration Number OPD Number...
NATIONAL CENTRE FOR DISEASE INFORMATICS AND RESEARCH Indian Council of Medical Research, Bengaluru (A Study on the Magnitude and Pattern of Causes of Heart Failure A Feasibility Study) I IDENTIFYING INFORMATION
More informationComorbidity Level 1 Level 2 Level 3 Comments Reference Diabetes Yes Unknown
Comorbidity Level 1 Level 2 Level 3 Comments Reference Diabetes HbA1c If medication; - Insulin - Oral antidiabetic - Both - Diet - treatment : Fasting blood sugar 7 mmol/l or post glucose 11.1 mmol/l and/or
More informationNothing to Disclose. Severe Pulmonary Hypertension
Severe Ronald Pearl, MD, PhD Professor and Chair Department of Anesthesiology Stanford University Rpearl@stanford.edu Nothing to Disclose 65 year old female Elective knee surgery NYHA Class 3 Aortic stenosis
More informationCCRN Review Cardiovascular
CCRN Review Cardiovascular Leanna R. Miller, RN, MN, CCRN-CMC, PCCN-CSC, CEN, CNRN, CMSRN, NP Education Specialist LRM Consulting Nashville, TN Angina Definition discomfort that occurs when oxygen demand
More informationDiagnosis & Management of Heart Failure. Abena A. Osei-Wusu, M.D. Medical Fiesta
Diagnosis & Management of Heart Failure Abena A. Osei-Wusu, M.D. Medical Fiesta Learning Objectives: 1) Become familiar with pathogenesis of congestive heart failure. 2) Discuss clinical manifestations
More informationDr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college
Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms
More informationHeart Failure Update John Coyle, M.D.
Heart Failure Update 2011 John Coyle, M.D. Causes of Heart Failure Anderson,B.Am Heart J 1993;126:632-40 It It is now well-established that at least one-half of the patients presenting with symptoms and
More informationELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY
ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents Eligibility criteria for Pulmonary Arterial Hypertension therapy...2-6 Initial Application for funding of Pulmonary Arterial Hypertension
More informationHF Patient Management Tool July 2017
Heart Failure Form Page 1 PMT FORM SELECTION HF ARRIVAL AND ADMISSION INFORMATION Patient ID: Legend: Elements in bold are required Internal Tracking ID: Physician/Provider NPI: Arrival Date and Time:
More informationMITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT. Irene Frantzis P year, SGUL Sheba Medical Center
MITRAL VALVE DISEASE- ASSESSMENT AND MANAGEMENT Irene Frantzis P year, SGUL Sheba Medical Center MITRAL VALVE DISEASE Mitral Valve Regurgitation Mitral Valve Stenosis Mitral Valve Prolapse MITRAL REGURGITATION
More informationPOST-OP CARDIAC SURGERY PHYSICIAN S ORDER SHEET USE BALLPOINT PEN ONLY. CARDIAC INTENSIVE CARE UNIT
PHYSICIAN S SHEET Automatically Activate, if not in agreement, cross out and initial Activated by Checking Box ALLERGIES: None known YES Patient s Height: Patient s Weight: ALL MEDICATION and INTRAVENOUS
More informationCASE DISCUSSION. Dr JAYASREE VEERABOINA 2nd yr PG MS OBG
CASE DISCUSSION Dr JAYASREE VEERABOINA 2nd yr PG MS OBG Normal Cardiovascular changes in Pregnancy CARDIAC OUTPUT 5 th wk -- starts 12 wks -- 30-35% 30-32 wks -- 40% During labour -- 50% After delivery
More informationDAY1_CARDIOVASCULAR PRACTICE QUESTIONS
DAY1_CARDIOVASCULAR PRACTICE QUESTIONS 1 P age 1. A 59-year-old male is admitted complaining of chest pain and dyspnea. ST elevation and T-wave inversion were seen on the ECG in V2, V3, and V4. IV thrombolytic
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationCardiac Disease in Fatty Acid Oxidation Disorders
Cardiac Disease in Fatty Acid Oxidation Disorders Kathryn Chatfield, MD, PhD Assistant Professor of Pediatrics Division of Cardiology University of Colorado School of Medicine Children s Hospital Colorado
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-25 U/L 10-35 U/L 10-30 U/L 10-25 U/L 10-30 U/L 10-35 U/L 10-25 U/L 10-35 U/L 10-25 U/L 10-20 U/L 10-35 U/L Albumin 0-6
More informationChemistry Reference Ranges and Critical Values
Alanine Aminotransferase (ALT, SGPT) 3-9 years 9-18 years 1-9 years 9-18 years 10-30 U/L 10-30 U/L 10-20 U/L Albumin 0-6 days 6 days - 37 months 37 months - 7 years 7-20 years 2.6-3.6 g/dl 3.4-4.2 g/dl
More informationModule 1: Evidence-based Education for Health Care Professionals
Module 1: Evidence-based Education for Health Care Professionals Heart Failure is a HUGE Problem Prevalence Incidence Mortality Hospital Discharges Cost 1 5,300,000 660,000 284,965 1,084,000 $34.8 billion
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationRestrictive Cardiomyopathy in Cats (a Type of Heart-Muscle Disease) Basics
Restrictive Cardiomyopathy in Cats (a Type of Heart-Muscle Disease) Basics OVERVIEW The heart of the cat is composed of four chambers; the top two chambers are the left and right atria and the bottom two
More informationHeart. Severe. Failure. Congestive heart failure (CHF) is very. What you can do for your patients
Focus on CME at the University of Université Manitoba de Sherbrooke By Anne Fradet, MD, FRCP, CSPQ Severe Heart Failure What you can do for your patients The case of Mr. White Mr. White, 72, comes to your
More informationDysrhythmias. Dysrythmias & Anti-Dysrhythmics. EKG Parameters. Dysrhythmias. Components of an ECG Wave. Dysrhythmias
Dysrhythmias Dysrythmias & Anti-Dysrhythmics Rhythm bad in the heart: Whitewater rafting Electrical impulses coordinate heart Reduction in Cardiac Output PEA Asystole Components of an ECG Wave EKG Parameters
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationHEART FAILURE. Study day November 2018 Sarah Briggs
HEART FAILURE Study day November 2018 Sarah Briggs Overview and Introduction This course is an introduction and overview of heart failure. Normal heart function and basic pathophysiology of heart failure
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More informationHeart failure hospitalizations with preserved or reduced ejection fraction
Clinical profile and in-hospital outcomes in patients admitted for heart failure with preserved or reduced ejection fraction. EPI-CARDIO prospective registry Tajer, C; Mariani, J; de Abreu, M; Charask,
More informationHeart Failure (HF) - Primary Care Flow Charts. Pre diagnosis Symptoms or signs suggestive of HF
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationHeart Failure (HF) - Primary Care Flow Charts. Symptoms or signs suggestive of HF. Pre diagnosis. Refer to the Heart Failure Clinic at VHK for
Heart Failure (HF) - Primary Care Flow Charts Pre diagnosis Symptoms or signs suggestive of HF 12 lead ECG Normal examination and 12 lead ECG HF highly unlikely Abnormal 12 lead ECG HF Possible Arrange
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationPeripartum Cardiomyopathy. Lavanya Rai Manipal
Peripartum Cardiomyopathy Lavanya Rai Manipal Definition - PPCM - Dilated cardiomyopathy of unknown cause resulting in cardiac failure that occurs in the peripartum period in women without any preexisting
More informationCHAPTER-I MYOCARDIAL INFARCTION
CHAPTER-I MYOCARDIAL INFARCTION Definition A myocardial infarction, more commonly known as MI or acute myocardial infarction (AMI) or heart attack is a condition where there is interruption of blood supply
More informationNCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT
NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT CONTENTS PATIENTS ADMITTED WITH HEART FAILURE...4 Demographics... 4 Trends in Symptoms... 4 Causes and Comorbidities
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More information6 th Floor and 7 East Nurses Guide Intravenous Drip List Approved for RN Administration University of Kentucky Chandler Medical Center
RATE Abciximab (Reopro) Alteplase (tpa, Activase) All units 6S and 6W ONLY Platelet aggregation inhibitor Thrombolytic agent Bolus: 0.25 mg/kg IV over 5 min Infusion: 0.125 0.9 mg/kg (max 90 mg); 10% of
More informationTable 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use
Table 1 Baseline characteristics of 60 hemodialysis patients with atrial fibrillation and warfarin use Baseline characteristics Users (n = 28) Non-users (n = 32) P value Age (years) 67.8 (9.4) 68.4 (8.5)
More informationHemodynamic Monitoring
Perform Procedure And Interpret Results Hemodynamic Monitoring Tracheal Tube Cuff Pressure Dean R. Hess PhD RRT FAARC Hemodynamic Monitoring Cardiac Rate and Rhythm Arterial Blood Pressure Central Venous
More information